Gagliardini, Roberta
 Distribuzione geografica
Continente #
NA - Nord America 1.206
EU - Europa 1.041
AS - Asia 643
SA - Sud America 128
Continente sconosciuto - Info sul continente non disponibili 34
AF - Africa 22
OC - Oceania 2
Totale 3.076
Nazione #
US - Stati Uniti d'America 1.169
SG - Singapore 310
DE - Germania 226
PL - Polonia 209
FR - Francia 167
SE - Svezia 149
CN - Cina 143
IT - Italia 105
BR - Brasile 103
VN - Vietnam 56
UA - Ucraina 47
GB - Regno Unito 46
IN - India 39
IE - Irlanda 30
ID - Indonesia 19
CA - Canada 17
FI - Finlandia 17
RU - Federazione Russa 15
BD - Bangladesh 13
HK - Hong Kong 13
JP - Giappone 12
AR - Argentina 11
TR - Turchia 11
MX - Messico 10
NL - Olanda 7
ZA - Sudafrica 7
IR - Iran 5
JM - Giamaica 5
BE - Belgio 4
SA - Arabia Saudita 4
TN - Tunisia 4
CL - Cile 3
EC - Ecuador 3
LT - Lituania 3
MA - Marocco 3
AT - Austria 2
AU - Australia 2
CO - Colombia 2
DK - Danimarca 2
EG - Egitto 2
ES - Italia 2
EU - Europa 2
IQ - Iraq 2
KE - Kenya 2
MD - Moldavia 2
NI - Nicaragua 2
PA - Panama 2
PH - Filippine 2
VE - Venezuela 2
AG - Antigua e Barbuda 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BO - Bolivia 1
CG - Congo 1
CH - Svizzera 1
EE - Estonia 1
ET - Etiopia 1
GH - Ghana 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MM - Myanmar 1
MT - Malta 1
NP - Nepal 1
OM - Oman 1
PE - Perù 1
PK - Pakistan 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 3.044
Città #
Kraków 199
Chandler 183
Singapore 154
Ashburn 97
San Jose 85
New York 62
Jacksonville 52
Beijing 31
Dublin 30
Redmond 30
San Mateo 29
Los Angeles 27
Milan 27
The Dalles 26
Houston 24
Ann Arbor 20
Ho Chi Minh City 20
Lauterbourg 20
Dallas 19
Jakarta 19
Nanjing 18
Boston 17
Dearborn 17
Hanoi 15
Wilmington 15
Nürnberg 14
Cattolica 13
Hong Kong 12
Lawrence 12
Rome 12
Changsha 11
Frankfurt am Main 11
Lancaster 11
Tokyo 10
Woodbridge 10
Nanchang 9
Santa Clara 9
Buffalo 8
Fairfield 8
Roubaix 8
Seattle 8
Brooklyn 7
Izmir 7
Montreal 7
Redwood City 7
São Paulo 7
Warsaw 7
Atlanta 6
Kunming 6
Munich 6
Paris 6
Princeton 6
Pune 6
Bexley 5
Johannesburg 5
Manchester 5
Marseille 5
Orem 5
Shenyang 5
Toronto 5
Verona 5
Washington 5
Amsterdam 4
Augusta 4
Brussels 4
Chennai 4
Falls Church 4
Hangzhou 4
Hebei 4
Little Rock 4
Mexico City 4
Stockholm 4
Anápolis 3
Biên Hòa 3
Boardman 3
Calgary 3
Cambridge 3
Clearwater 3
Des Moines 3
Guangzhou 3
Helsinki 3
Jinan 3
Kingston 3
Leawood 3
London 3
Phoenix 3
Poplar 3
Portsmouth 3
Queens 3
San Francisco 3
Turin 3
University Park 3
Andover 2
Ankara 2
Araçatuba 2
Bari 2
Brasília 2
Bremen 2
Chicago 2
Council Bluffs 2
Totale 1.641
Nome #
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 233
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 225
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 221
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 221
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 211
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 198
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 194
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 189
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 171
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 168
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 156
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 151
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 145
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 140
Liver fibrosis progression and clinical outcomes are intertwined: Role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCVcoinfected patients with detectable HCV-RNA A MASTER cohort study 138
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study 117
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 111
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 87
Totale 3.076
Categoria #
all - tutte 11.584
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.584


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022200 0 11 4 17 6 15 4 36 14 29 26 38
2022/2023426 66 69 29 68 28 55 7 50 44 1 8 1
2023/2024205 6 63 4 23 12 50 14 1 0 2 22 8
2024/2025360 3 14 21 11 40 7 8 29 73 25 70 59
2025/2026846 130 10 40 112 174 37 156 40 37 65 33 12
2026/202754 24 30 0 0 0 0 0 0 0 0 0 0
Totale 3.076